Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 28, 2025

Kinross Gold and Carter's have been highlighted as Zacks Bull and Bear of the Day

View original at nasdaq.com
Kinross Gold and Carter's have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – November 28, 2025 – Zacks Equity Research shares Kinross Gold KGC, as the Bull of the Day and, Carter’s CRI, as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Zacks Earnings ESP forecasting potential 38.84% earnings beat for Kinross in upcoming report

    80% confidence
  • Coca-Cola expects the number of billion-dollar brands to keep growing

    80% confidence
  • Coca-Cola has almost 30 billion-dollar brands accounting for nearly one-quarter of all billion-dollar brands in the industry

    80% confidence
  • Quantum Computing is the next technological revolution and could be even more advanced than AI

    80% confidence
  • Zacks Consensus Estimate for Coca-Cola's 2025 and 2026 EPS implies year-over-year growth of 3.5% and 8% respectively

    80% confidence
  • Carter's key resistance level to watch is $33.40 for potential breakout

    80% confidence
  • Carter's has Zacks Rank #5 (Strong Sell) rating

    80% confidence
  • Kinross trades at only 16.5x forward earnings with PEG ratio of 0.4

    80% confidence
  • Coca-Cola stock carries Zacks Rank #3 (Hold)

    80% confidence
  • Kinross Gold has Zacks Rank #1 (Strong Buy) rating

    80% confidence
  • Since 2000, Zacks' top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

    80% confidence
  • Kinross is expected to grow earnings at 40.85% annually over the next three to five years

    80% confidence
  • Carter's sales expected to decline 0.15% in 2025, followed by only 1.71% rebound in 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com